Stockpolly
Search
XFOR · NASDAQ · Biotechnology

X4 Pharmaceuticals (XFOR)

Commercializing XOLREMDI while advancing mavorixafor for chronic neutropenia.

$4.01
Pre-market−0.04 (−0.87%)
At close$4.05(−0.61%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue0001112922339
Cost of revenue100000500012
Gross profit−1000012411227
272537343537332829262224
Research & development191520211922181817181515
81017131615151012779
General & administrative000000000079
Other expenses000000000000
Operating income−27−25−37−34−35−36−9−26−28−24−20−16
256−14125−2−4101−2000
Interest income111221111222
Interest expense222222222222
Other non-operating income0−813−12702−12−30−2−2−2
Income before tax−2−19−5291−37−400−26−30−24−20−16
Income tax expense000000000000
Net income from continuing operations−2−19−5291−37−400−26−30−24−20−16
Net income−2−19−5291−37−400−26−30−24−20−16
EPS, basic−$0.35−$2.89−$7.77$13.60−$5.48−$6.00$0.04−$3.47−$0.69−$0.22−$0.16−$0.13
EPS, diluted−$0.35−$2.89−$7.77$13.57−$5.48−$6.00$0.04−$3.47−$0.69−$0.22−$0.16−$0.13
Weighted average shares, basic7777777743111126126
Weighted average shares, diluted7777777743111126126
EBITDA−27−17−5093−34−373−23−27−22−18−13
Depreciation & amortization100000000001
EBIT−27−17−5093−34−373−23−28−22−18−14